Monthly seminar series launched
We are launching the DEMON Network Monthly Seminar Series in response to huge demand from our members.
Seminars will include live streamed events covering a range of topics related to the application of data science and AI to dementia research and healthcare. All seminars are freely available to Network members and will be advertised in our newsletter. (Join here for free if you’re not already a member of the DEMON Network.) The first event, and each alternate month thereafter, will be hosted jointly with the UK Dementia Research Institute (DRI) with whom we have an official partnership. Many of our members have expressed an interest in giving talks, but we welcome additional speaker suggestions. We’re also interested in mixing up the format, for example holding debates and interactive workshops. Contact us with your ideas.
This Friday 2nd October you are invited to the inaugural seminar featuring talks and Q&A with two outstanding speakers:
Dr Timothy Rittman
Senior Clinical Research Associate, University of Cambridge
Consultant Neurologist, Addenbrookes Hospital
DEMON Network East UK Regional Lead
Understanding tauopathies – from neuroimaging to mechanisms
Neurodegenerative tauopathies such as Progressive Supranuclear Palsy and Corticobasal Degeneration allow us to investigate how tau and its associated pathologies cause clinical syndromes. Neuroimaging gives us the opportunity to study these diseases in vivo, to understand how pathology links to macroscopic changes in brain structure and functional organisation, and ultimately to clinical syndromes. In this talk I will cover some of the advances we have made to understand the links between tau pathology, brain volume loss and functional brain networks. I will also discuss how these advanced neuroimaging techniques that are shedding light on neuropathology, can become clinically useful biomarkers.
Prof Valentina Escott-Price
Group Leader at UK DRI at Cardiff
From genes to treatment or how to find a needle in a haystack
Advances in the treatment of Alzheimer’s Disease (AD) are more pressing than ever due to socioeconomic needs. The field notably shifted away from a purely neurocentric view, largely since Genome-Wide Association Studies identified several risk genes that are primarily expressed in microglia and not in neurons. The challenge is now to leverage the massive amount of genetic data to decipher disease mechanisms and design effective therapeutic interventions for AD. In my talk I will provide an overview of the methodologies for reliable detection of individuals at high risk of AD using common genomic variation, outline my current research in incorporating rare variants for disease probability calculation, describe data and methods needed to recover “missing heritability” in AD, and challenges associated with it.